Rochester wins COX-2 patent, files suit
The patent entitles the University of Rochester to royalties on the sale of all COX-2 inhibitors. Shortly after the patent was awarded, attorneys representing the University of Rochester filed an infringement suit in federal court against Searle, Chicago, and Pfizer Inc., New York, which jointly market Celebrex.
The patent entitles the University of Rochester to royalties on the sale of all COX-2 inhibitors. Shortly after the patent was awarded, attorneys representing the University of Rochester filed an infringement suit in federal court against Searle, Chicago, and Pfizer Inc., New York, which jointly market Celebrex.
"We've filed a lawsuit against Searle and Pfizer to ensure that our legal rights are preserved, though we intend to begin discussions with both companies in an effort to negotiate licensing agreements," said Terrance O'Grady, an attorney for the University.
Searle disputes claim
Searle disputes the validity of the University of Rochester claim and said that it lacks novelty and enablement â two requirements of U.S. patent law.
The University's patent lacks novelty because COX-2 inhibitors are not a new invention, according to Searle patent lawyers, who added that a significant body of literature existed before the patent was filed in 1992 that described the potential benefits of treating people with COX-2 drugs. In lacking enablement, Searle maintains the patent fails to describe or teach, with any particularity, how to put the invention into practice and claims that the sweeping nature of the University's patent is flawed. According to Searle, the University patent is a method-of-treatment patent covering how to apply the concept in patients, in contrast to Searle's compound patent that specifically describes a molecule.
Searle also expressed disappointment about the way the suit was handled by the University. "We are disappointed to hear of this development from the media, rather than being contacted directly by the University of Rochester. Uncertainty in the market about such an important and beneficial pharmaceutical agent is not in anyone's best interest â particularly arthritis patients," said Richard U. De Schutter, senior executive vice president and chief administrative officer of Pharmacia Corp. "We have complete confidence in our COX-2 patent estate and will vigorously defend against this challenge." PR
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
